Answers are grounded in this paper and cite their sources.
9MW2821, a new generation site-specific conjugated novel nectin-4-targeting antibody-drug conjugates (ADC) being developed by Mabwell, is the first drug candidate to enter clinical study among the nectin-4-targeting ADCs developed by Chinese companies. The Phase 2 clinical trial aims to evaluate the efficacy and safety of 9MW2821 as monotherapy or in combination in patients with locally advanced or metastatic Triple Negative Breast Cancer (TNBC).
No takes yet. Share an insight, caveat, or question.
Peter Hofland (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: